

Cost-effectiveness analysis of Stockholm 3 testing compared to PSA as the primary blood test in the prostate cancer diagnostic pathway: A decision tree approach

Bettina Wulff Risør^{1,2,3*}, Nasrin Tayyari Dehbarez^{1,2}, Jacob Fredsøe^{4,5}, Karina Dalsgaard Sørensen^{4,5}, Bodil

Ginnerup Pedersen^{5,6}

¹DEFACTUM, Central Denmark Region, Olof Palmes Allé 15, DK-8200 Aarhus N, Denmark

²Danish Center for Healthcare Improvements (DCHI), Aalborg University, Fredrik Bajers Vej 5, DK-9220 Aalborg, Denmark

³Nordic Institute of Health Economics, Gammel Munkegade 1, 1, DK-8000 Aarhus C, Denmark

⁴Department of Molecular Medicine (MOMA), Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark

⁵Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark

⁶Department of Radiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark

***Corresponding author:** Bettina Wulff Risør, DEFACTUM, Central Denmark Region, Olof Palmes Allé 15, DK-8200 Aarhus N, Denmark. Phone: +45 42769416, email: betris@rm.dk, ORCID ID: 0000-0003-3701-074X

Funding: This study was financially supported by Innovation Fund Denmark and NordForsk (ID no.: 8114-00027B).

Competing interest statement: The authors declare that they have no competing interests.

Diagnostic strategy
cMRI = cMRI_M
cMRI_targeted_biopsy = cMRI_targeted_biopsy
cPSA = 2.37
cSEPSS = 5.00
cSTHLM3 = 203.22
cURO = 0.00

